Saturday, November 23, 2019 11:26:58 AM
Aquestive Therapeutics -FDA approval for Exservan, its riluzole oral film for patients with ALS.
Expect a run come Monday morning folks. Wedbush price target $34
This was suddenly and so unexpected to be approved Friday evening. Pdufa was 30th
Recent AQST News
- Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock • GlobeNewswire Inc. • 03/25/2024 12:00:25 PM
- Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock • GlobeNewswire Inc. • 03/20/2024 01:49:43 AM
- Aquestive Therapeutics Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/19/2024 08:01:00 PM
- Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting • GlobeNewswire Inc. • 03/14/2024 09:23:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:36:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:36:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:35:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:35:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:35:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:35:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:34:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:14:46 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 10:12:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 10:09:47 PM
- Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/05/2024 10:05:49 PM
- Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET • GlobeNewswire Inc. • 02/21/2024 01:00:00 PM
- Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting • GlobeNewswire Inc. • 02/15/2024 01:00:35 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:24:42 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/12/2024 10:02:07 PM
- Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference • GlobeNewswire Inc. • 01/30/2024 01:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 03:46:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 01:51:28 PM
- Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film • GlobeNewswire Inc. • 12/05/2023 01:00:00 PM
- Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting • GlobeNewswire Inc. • 11/10/2023 01:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 10:04:06 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM